SCHEMBL212369

SCHEMBL212369

CN1CCN(C)C1=NOS(=O)(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 9/20 0.49
MAPT P10636 8/20 0.49
NPSR1 Q6W5P4 6/20 0.49
MPI P34949 5/20 0.49
XBP1 P17861 4/20 0.49
HSP90AA1 P07900 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPK1 P28482 4/20 0.48
LMNA P02545 4/20 0.47
RAB9A P51151 4/20 0.47
S1PR2 O95136 3/20 0.47
HTT P42858 3/20 0.47
PKM P14618 2/20 0.47
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
KDM4E B2RXH2 4/20 0.46
TP53 P04637 1/20 0.46
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15389458 0.85 MEN1 (0.52) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL27927223 0.80 HTR2A (0.40) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL17257009 0.75 MAPK1 (0.39) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL17257012 0.75 MAPK1 (0.39) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL2048835 0.73 KMT2A (0.60) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL2051857 0.73 MAPK1 (0.54) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL2044122 0.71 MAPK1 (0.59) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL2044123 0.71 MAPK1 (0.59) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL2047654 0.71 MAPT (0.66) KMT2AMEN1ALDH1A1MAPTNPSR1
SCHEMBL384594 0.70 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US claimed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US claimed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US claimed
US-10241399-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent BASF SE (DE) 2019-03-26 US disclosed
EP-2668156-B1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT BASF SE (DE) 2018-10-31 EP disclosed
US-9310677-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent BASF (DE) 2016-04-12 US disclosed
US-20160060214-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT BASF SE (DE) 2016-03-03 US disclosed
US-20130308219-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT BASF SE (DE) 2013-11-21 US disclosed
US-8541509-B2 Polymers functionalized with protected oxime compounds BRIDGESTONE CORPORATION (JP) 2013-09-24 US disclosed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US disclosed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US disclosed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10241399-B2 Polymerizable composition comprising an oxime sulfonate as thermal curing agent SULT1E1, COX6B1, SULT1A1 KMT2A 930/4885MEN1 4751/4885ALDH1A1 776/4885
US-20160060214-A1 POLYMERIZABLE COMPOSITION COMPRISING AN OXIME SULFONATE AS THERMAL CURING AGENT SULT1E1, COX6B1, SULT1A1 KMT2A 930/4885MEN1 4751/4885ALDH1A1 776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.